.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 5,855,908

« Back to Dashboard

Details for Patent: 5,855,908

Title: Non-dissolvable drug-containing dosage-forms for use in the transmucosal delivery of a drug to a patient
Abstract:Compositions and methods of manufacture for producing a medicament composition capable of absorption through the mucosal tissues of the mouth, pharynx, and esophagus. The present invention relates to such compositions and methods which are useful in administering lipophilic and nonlipophilic drugs in a dose-to-effect manner such that sufficient drug is administered to produce precisely a desired effect. The invention also relates to manufacturing techniques that enable therapeutic agents to be incorporated into nondissolvable drug containment matrixes which are capable of releasing the drug within a patient's mouth. An appliance or holder is preferably attached to the drug containment matrix. Employing the present invention the drug may be introduced into the patient's bloodstream almost as fast as through injection, and much faster than using the oral administration route, while avoiding the negative aspects of both of these methods. The nondissolvable drug containment matrix may include permeation enhancers to increase the drug absorption by the mucosal tissues of the mouth. The matrix composition may also include pH buffering agents to modify the salival pH thereby increasing the absorption of the drug through the mucosal tissues.
Inventor(s): Stanley; Theodore H. (Salt Lake City, UT), Hague; Brian (West Valley City, UT)
Assignee: University of Utah Research Foundation (Lake City, UT)
Filing Date:Nov 15, 1994
Application Number:08/339,655
Claims:1. A drug-containing dosage-form for use in the transmucosal delivery of a drug to a patient, the dosage-form consisting essentially of:

(a) a drug containment matrix which is nondissolvable by the saliva in the mouth of the patient and which is designed to be nonfrangible in the mouth of the patient, the drug containment matrix containing a pharmacologically effective dose of a drug so that the nondissolvable drug containment matrix is capable of being sucked on or passively held within the mouth and is configured to release the drug within the mouth of the patient for adsorption through mucosal tissues of the mouth, pharynx, and esophagus, the drug containment matrix also having a holder means secured thereto, the holder means being configured to permit convenient insertion and removal of the drug containment matrix into and out of the mouth of the patient in a dose-to-effect manner; and

(b) a buffer including citric acid/sodium citrate held within the drug containment matrix.

2. A drug-containing dosage-form as recited in claim 1, wherein the buffer further includes a phosphate buffer system.

3. A drug-containing dosage-form as recited in claim 1, wherein the buffer is incorporated in an amount of about 1% by weight.

4. A drug-containing dosage-form for use in the transmucosal delivery of a drug to a patient, the dosage-form consisting essentially of:

(a) a drug containment matrix which is nondissolvable by the saliva in the mouth of the patient and which is designed to be nonfrangible in the mouth of the patient, the drug containment matrix containing a pharmacologically effective dose of a drug so that the nondissolvable drug containment matrix is capable of being sucked on or passively held within the mouth and is configured to release the drug within the mouth of the patient for adsorption through mucosal tissues of the mouth, pharynx, and esophagus, the drug containment matrix also having a holder means secured thereto, the holder means being configured to permit convenient insertion and removal of the drug containment matrix into and out of the mouth of the patient in a dose-to-effect manner; and

(b) a buffer including a phosphate buffer system held within the drug containment matrix.

5. A drug-containing dosage-form as recited in claim 4, wherein the buffer is incorporated in an amount of about 1% by weight.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc